Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Nagusman Danil; Sharvianty Arifuddin; Eddy Hartono; Nur Rakhmah; Ajardiana Ajardiana; Syahrul Rauf; Andi Alfian Zainuddin

doi:10.24198/obgynia/v6n1.451

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Nagusman Danil,^(1*) Sharvianty Arifuddin,⁽²⁾ Eddy Hartono,⁽³⁾ Nur Rakhmah,⁽⁴⁾ Ajardiana Ajardiana,⁽⁵⁾ Syahrul Rauf,⁽⁶⁾ Andi Alfian Zainuddin,⁽⁷⁾

(1) Universitas Hasanuddin, Indonesia
(2) Divisi Onkologi Ginekologi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin, Indonesia
(3) Divisi Obstetri dan Ginekologi Sosial, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin, Indonesia
(4) Divisi Obstetri dan Ginekologi Sosial, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin, Indonesia
(5) Divisi Obstetri dan Ginekologi Sosial, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin, Indonesia
(6) Divisi Onkologi Ginekologi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin, Indonesia
(7) Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin, Indonesia
(*) Corresponding Author

Abstract

Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB.
Metode: Sebanyak 30 pasien yang baru terdiagnosis kanker serviks stadium IIB dibagi menjadi dua kelompok terapi kombinasi yaitu kelompok Paclitaxel-Carboplatin-Ifosfamide (TIP) dan Paclitaxel-Carboplatin (TP). Volume tumor dan respon terapi diukur sebelum dan sesudah tiga siklus kemoterapi.
Hasil:Tingkat penurunan rata-rata volume tumor pada kelompok Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin sebesar (23,66% vs 39,08%). Tidak ada perbedaan secara bermakna angka respon parsial, angka respon progresif dan tidak ada respon antara kelompok dengan Paclitaxel-Carboplatin-Ifosfamide dengan kelompok Paclitaxel-Carboplatin dengan p > 0,05. Hasil antara Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin pada respon parsial (46,7 % vs 73,3%), respon progresif (13,3% vs 13.3%), dan tidak ada respon (40,0 % vs 1,3%) dan toksisitas kelas 2 lebih dominan pada kelompok Paclitaxel-Carboplatin-Ifosfamide yaitu mual, kerontokan (53,3%) dan fatique, muntah (46,7%).
Kesimpulan: Regimen kemoterapi kombinasi Paclitaxel-Carboplatin lebih efektif dalam menurunkan ukuran tumor kanker serviks stadium IIB dengan efek samping yang lebih minimal dibandingkan kombinasi Paclitaxel-Carboplatin-Ifosfamide.

Comparison of Therapy Response and Toxicity of Combination Chemotherapy Regimens Between Paclitaxel, Carboplatin And Ifosfamide (PCI) with Paclitaxel and Carboplatin (PC) in Stadium IIB Cervical Cancer

Abstract
Objective: To compare the therapeutic response and toxicity of a combination chemotherapy regimen of Paclitaxel Carboplatin Ifosfamide with Paclitaxel Carboplatin in stage IIB cervical cancer.
Methods: A total of 30 patients newly diagnosed with stage IIB cervical cancer were divided into two combination therapy groups, namely the Paclitaxel-Carboplatin-Ifosfamide (PCI) and Paclitaxel-Carboplatin (PC) groups. Tumor volume and clinical response were measured before and after three cycles.
Result: The average reduction rate of tumor volume in the Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin groups was (23.66% vs 39.08%). There was no significant difference in the partial response rate, progressive response rate and no response between the Paclitaxel-Carboplatin-Ifosfamide group and the Paclitaxel-Carboplatin group with p > 0.05. Results between Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin on partial response (46.7% vs 73.3%), progressive response (13.3% vs 13.3%), and no response (40.0% vs 1, 3%) and class 2 toxicity was more dominant in the Paclitaxel-Carboplatin-Ifosfamide group namely nausea, hair loss (53.3%) and fatigue, vomiting (46.7%).
Conclusion: The Paclitaxel-Carboplatin combination chemotherapy regimen is more effective in reducing the tumor size of stage IIB cervical cancer with lower side effects than the Paclitaxel-Carboplatin-Ifosfamide combination.

Key words: cervical cancer, chemotherapy, side effects

Keywords

kanker serviks, kemoterapi, efek samping

Full Text:

PDF

References

GLOBOCAN. Global Cancer Data: GLOBOCAN 2018 [Internet]. 2018. Tersedia pada: https://www.uicc.org/news/global-cancer-data-globocan-2018

Kementerian Kesehatan Republik Indonesia. Kanker Serviks. Pedoman Nasional Pelayanan Kedokteran. Jakarta: Kementerian kesehatan Republik Indonesia; 2018.

Bermudez A, Bhatla N, Leung E. Cancer of the cervix uteri. Int J Gynecol Obstet [Internet]. 2015;131:S88–95. Tersedia pada: http://dx.doi.org/10.1016/j.ijgo.2015.06.004

Shen Y, Yang L, Wang Z. Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy. Oncol Lett. 2012;3(3):641–5.

Noviyani R, Suwiyoga K, Lesmana I, Niruri R, Tunas K, Budiana AING. Differences of Tumor Masses and Hemoglobin Levels in Cervical Cancer Squamous Cell Type Patients Treated With Combination of Paclitaxel and Carboplatin Chemotherapy. Bali Med J. 2014;3(1):15.

Sannu A, Radha R, Voelcker G. Ifosfamide-Induced Malignancy of Ureter and Bladder. Cureus. 2017;9(8).

Voelcker G. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anticancer Drugs. 2018;29(1):75–9.

Yang L, Guo J, Shen Y, Cai J, Xiong Z, Dong W, et al. Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer. Int J Clin Exp Med. 2015;8(8):13690–8.

Choi HJ, Paik ES, Choi CH, Kim TJ, Lee YY, Lee JW, et al. Response to Combination Chemotherapy with Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients with Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. Int J Gynecol Cancer. 2018;28(7):1333–41.

Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: An update. Expert Rev Anticancer Ther. 2015;15(10):1171–81.

Mabuchi S, Isohashi F, Okazawa M, Kitada F, Maruoka S, Ogawa K, et al. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients. J Gynecol Oncol. 2017;28(1):1–13.

Budiana ING, Febiani M, Prayudi PKA. Drug-induced encephalopathy in cervical cancers with ifosfamide. Neurol Spinale Med Chir. 2020;3(1):16–20.

DOI: http://dx.doi.org/10.24198/obgynia/v6n1.451